Aspira Women’s Health Reports Modest Revenue Increase and Significant Cost Reductions for Fiscal Year 2025

Aspira Women’s Health Inc. reported a modest increase in revenue for the fiscal year ending December 31, 2025, with total revenue reaching $9.216 million, up from $9.182 million in 2024. Despite a 7% decrease in the volume of tests performed, the company maintained flat revenue by focusing on sales in more profitable regions, resulting in an increase in average unit price (AUP) for its tests. The AUP for Ova1Plus rose to $414 from $382, while OvaWatch increased to $394 from $362. The cost of revenue also decreased by 11% to $3.301 million, contributing to an 8% increase in gross profit, which totaled $5.915 million.

Aspira's operating expenses saw a significant reduction of 36%, dropping from $21.757 million in 2024 to $13.828 million in 2025. This decrease was primarily driven by a 63% reduction in sales and marketing expenses, which fell to $2.986 million from $8.146 million, and a 12% decrease in research and development costs. The company reported a loss from operations of $7.913 million, a 51% improvement compared to the previous year's loss of $16.278 million. However, total other expenses increased, leading to a net loss of $12.780 million, slightly better than the $13.094 million loss reported in 2024.

Strategically, Aspira has undergone significant organizational changes, reducing its workforce from 66 to 36 full-time employees to streamline operations and reduce cash burn. The company has also focused on enhancing its commercial strategy by reallocating resources to regions with favorable reimbursement profiles and optimizing marketing investments. These efforts have resulted in new contracts, including a partnership with Mayo Clinical Laboratories, which is expected to contribute to revenue growth in 2026.

Operationally, Aspira performed 22,515 OvaSuite tests in 2025, down from 24,305 in 2024. The company is actively working on expanding its product pipeline, particularly with the development of ENDOinform, a multi-marker test for endometriosis, and OVAinform, which assesses the risk of ovarian cancer. The total addressable market for these products is significant, with ENDOinform targeting approximately 6.5 million women in the U.S. affected by endometriosis.

Looking ahead, Aspira anticipates continued challenges, including the need for additional capital to support operations and product development. The company has expressed substantial doubt about its ability to continue as a going concern without raising further funds. Management plans to pursue various financing options, including public or private equity offerings and collaborations, to ensure the sustainability of its operations and to advance its product offerings in the gynecologic health market.